Semaglutide half-life: how long Ozempic stays in your system

Step 1: why a one-week half-life produces a once-weekly injection

Most small-molecule medicines are processed and excreted within hours. Semaglutide is different. Its molecular structure is engineered to bind tightly to albumin (a protein that circulates in the bloodstream) which dramatically slows breakdown and keeps it active far longer. The result is a plasma half-life of around 165 to 184 hours, or roughly seven days. That single fact is the reason the injection schedule works as it does: one dose per week is enough to maintain therapeutic blood levels without the peaks and troughs you would get from a short-acting drug.

This long half-life also means that missing a dose, or injecting a day late, does not immediately undo the previous week's concentration. The semaglutide medicines information page covers what to do with a missed dose in full, but the short answer is always to follow your prescriber's guidance and the patient information leaflet rather than trying to make up for lost time with a double dose.

A common assumption is that you should feel the effects within a day or two of your first injection. In practice, steady-state concentrations (the point at which the amount entering the body each week roughly equals the amount leaving) are not reached until after four to five doses. Clinical effects, including appetite reduction, often track that curve. Worth knowing before judging whether treatment is working.

Step 2: understanding the washout period after stopping

Because the half-life of semaglutide sits at approximately one week, the standard pharmacological rule of thumb applies: full elimination takes five half-lives, or roughly five weeks. During those five weeks, the drug's effects taper off gradually rather than stopping sharply. Appetite typically returns as levels fall, which is why clinical guidance emphasises that long-term lifestyle changes need to run alongside treatment, not replace it.

The washout period has real practical implications. Reproductive guidance specifies a waiting period after stopping semaglutide before trying to conceive, your prescriber and the patient information leaflet carry the current recommendation. For anyone planning surgery, the anaesthetic team needs to know about GLP-1 medicines in advance, partly because gastric emptying slows on treatment and that effect does not vanish the moment the last dose is given.

It is also the reason that simply stopping Wegovy or Ozempic abruptly tends to result in weight regain. The drug does not store itself in fat tissue or produce a lingering pharmacological effect after it is gone; once the molecule clears, so does the appetite suppression. That is biology, not a failure of willpower. The patient experience with Wegovy covers this point in detail, including what prescribers typically discuss around stopping.

Step 3: Ozempic vs Wegovy, same molecule, different UK licences

Both Ozempic and Wegovy contain semaglutide, and their half-life is identical because the active molecule is the same. The critical difference is what each brand is licensed to treat in the UK. Wegovy and Ozempic are not interchangeable in a clinical or legal sense: Ozempic is authorised by the MHRA for type 2 diabetes management; Wegovy is the brand authorised for weight management in adults with a BMI of 30 or above, or 27 or above with a weight-related health condition. Using Ozempic for weight loss in the UK would mean using it outside its licensed indication, which is a matter for a prescriber to navigate, not something to arrange informally.

Dosing differs too. The dosing schedules for semaglutide across the brands are not the same: Wegovy's maintenance dose is 2.4 mg weekly (or 7.2 mg with the higher-dose pen approved in early 2026), while Ozempic's doses top out lower. Because the half-life is the same, the washout timeline above applies to both, but the clinical context is quite different.

For weight management specifically, Wegovy (not Ozempic) is the product supported by the STEP 1 clinical trial evidence and NICE's technology appraisal, as covered in detail on the Wegovy information page. The NHS also makes this distinction clearly: Ozempic is a diabetes medicine, and the MHRA has stated that GLP-1 medicines are not assessed for quick or cosmetic weight loss.

What is licensed for weight loss in the UK, and how to access it

Ozempic is not a weight-loss medicine in the UK. The two GLP-1-based medicines with UK licences for weight management are Wegovy (semaglutide) and Mounjaro (tirzepatide). Both are prescription-only medicines; neither can be legally supplied without a prescription following clinical assessment. The NHS medicines page for semaglutide sets out the approved indications clearly.

If you are trying to understand whether Ozempic contains semaglutide because you are interested in weight management, the direct answer is yes it does, but the relevant product for that purpose is Wegovy. For anyone exploring that route, where to get Wegovy in the UK explains the options, including what to look for in a regulated online pharmacy. The weight-loss treatment overview sets out both licensed options side by side if you are still deciding.

If you are ready to find out whether you are clinically suitable, our prescribers (a named, GPhC-registered Independent Prescriber reviews every consultation the same day it arrives) can assess you properly. Check your eligibility through a free consultation at any point.